Disclosures: Vinay Jahagirdar: Nothing to Disclose, Waqas Rasheed: Nothing to Disclose, Hanna Blaney: Nothing to Disclose, Hassam Ali: Nothing to Disclose, Jasmohan Bajaj: Bausch: Grant/Research Support, Sequana: Grant/Research Support, Cosmo: Grant/Research Support, Grifols: Grant/Research Support 2290 SIMVASTATIN INEFFECTIVE IN IMPROVING HEPATOPULMONARY SYNDROME IN CIRRHOSIS PATIENTS (HEPSIM TRIAL) RESULTS OF A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL [NCT05187715] Akhil Deshmukh 1 Shiv Kumar Sarin 1 Vishnu Girish 1 CHITRANSHU VASHISHTHA 1 Sukriti Baweja 1 Tushar Madke 1 Rahul khajuria 1 Harsh Tevethia 2 , 1 Institute Of Liver and Biliary Sciences, 2 INSTITUTE OF LIVER AND BILIARY SCIENCES(ILBS),NEW DELHI Background: Hepatopulmonary syndrome (HPS), marked by liver disease, intrapulmonary vascular dilatations, and abnormal oxygenation, causes significant morbidity and mortality
Although GSH failed to restore 5-hydroxytryptamine (5-HT/serotonin) levels in embryos treated with 10 M CdCl 2 , the Cd-induced suppression of heart rate was reversed by the serotonergic (5-HTergic) modulators quipazine and fluoxetine, suggesting the involvement of the 5-HT system in Cd-induced cardiotoxicity
Yeah, I think I used to think that it was from being martial arts
I reminded him taking the Liver Support
